186 related articles for article (PubMed ID: 33017867)
1. Predictive classifier for intensive treatment of head and neck cancer.
Zakeri K; Rotolo F; Lacas B; Vitzthum LK; Le QT; Gregoire V; Overgaard J; Hackshaw A; Zackrisson B; Parmar MKB; Burtness BA; Ghi MG; Sanguineti G; O'Sullivan B; Fortpied C; Bourhis J; Shen H; Harris J; Michiels S; Pignon JP; Mell LK;
Cancer; 2020 Dec; 126(24):5263-5273. PubMed ID: 33017867
[TBL] [Abstract][Full Text] [Related]
2. Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.
Mell LK; Shen H; Nguyen-Tân PF; Rosenthal DI; Zakeri K; Vitzthum LK; Frank SJ; Schiff PB; Trotti AM; Bonner JA; Jones CU; Yom SS; Thorstad WL; Wong SJ; Shenouda G; Ridge JA; Zhang QE; Le QT
Clin Cancer Res; 2019 Dec; 25(23):7078-7088. PubMed ID: 31420360
[TBL] [Abstract][Full Text] [Related]
3. Selection of Head and Neck Cancer Patients for Intensive Therapy.
Vitzthum LK; Park H; Zakeri K; Bryant AK; Feng C; Shen H; Cohen EEW; Murphy JD; Mell LK
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):157-166. PubMed ID: 31580929
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
Petit C; Lacas B; Pignon JP; Le QT; Grégoire V; Grau C; Hackshaw A; Zackrisson B; Parmar MKB; Lee JW; Ghi MG; Sanguineti G; Temam S; Cheugoua-Zanetsie M; O'Sullivan B; Posner MR; Vokes EE; Cruz Hernandez JJ; Szutkowski Z; Lartigau E; Budach V; Suwiński R; Poulsen M; Kumar S; Ghosh Laskar S; Mazeron JJ; Jeremic B; Simes J; Zhong LP; Overgaard J; Fortpied C; Torres-Saavedra P; Bourhis J; Aupérin A; Blanchard P;
Lancet Oncol; 2021 May; 22(5):727-736. PubMed ID: 33862002
[TBL] [Abstract][Full Text] [Related]
5. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
[TBL] [Abstract][Full Text] [Related]
6. Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer.
Dauzier E; Lacas B; Blanchard P; Le QT; Simon C; Wolf G; Janot F; Horiuchi M; Tobias JS; Moon J; Simes J; Deshmane V; Mazeron JJ; Mehta S; Zaktonik B; Tamura M; Moyal E; Licitra L; Fortpied C; Haffty BG; Ghi MG; Gregoire V; Harris J; Bourhis J; Aupérin A; Pignon JP;
Oral Oncol; 2019 Aug; 95():106-114. PubMed ID: 31345376
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.
Chen MM; Colevas AD; Megwalu U; Divi V
Oral Oncol; 2018 Sep; 84():71-75. PubMed ID: 30115479
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project.
Lassen P; Lacas B; Pignon JP; Trotti A; Zackrisson B; Zhang Q; Overgaard J; Blanchard P;
Radiother Oncol; 2018 Jan; 126(1):107-115. PubMed ID: 29100700
[TBL] [Abstract][Full Text] [Related]
9. Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
Zhao Y; Liu W; Sun M; Miao Q; Liu Y; Tian H; Su Y; Han F
Crit Rev Oncol Hematol; 2019 Mar; 135():39-46. PubMed ID: 30819445
[TBL] [Abstract][Full Text] [Related]
10. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group.
Lacas B; Carmel A; Landais C; Wong SJ; Licitra L; Tobias JS; Burtness B; Ghi MG; Cohen EEW; Grau C; Wolf G; Hitt R; Corvò R; Budach V; Kumar S; Laskar SG; Mazeron JJ; Zhong LP; Dobrowsky W; Ghadjar P; Fallai C; Zakotnik B; Sharma A; Bensadoun RJ; Ruo Redda MG; Racadot S; Fountzilas G; Brizel D; Rovea P; Argiris A; Nagy ZT; Lee JW; Fortpied C; Harris J; Bourhis J; Aupérin A; Blanchard P; Pignon JP;
Radiother Oncol; 2021 Mar; 156():281-293. PubMed ID: 33515668
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
13. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
[TBL] [Abstract][Full Text] [Related]
15. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
Maguire PD; Neal CR; Hardy SM; Schreiber AM
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
[TBL] [Abstract][Full Text] [Related]
16. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses.
Limkin E; Blanchard P; Lacas B; Bourhis J; Parmar M; Licitra L; Le QT; Yom SS; Fortpied C; Langendijk J; Vermorken JB; Bernier J; Overgaard J; Harris J; Pignon JP; Auperin A;
Radiother Oncol; 2024 Jan; 190():110011. PubMed ID: 37956890
[TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma.
Saksø M; Andersen E; Bentzen J; Andersen M; Johansen J; Primdahl H; Overgaard J; Eriksen JG
Acta Oncol; 2019 Oct; 58(10):1495-1501. PubMed ID: 31519130
[No Abstract] [Full Text] [Related]
18. Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Head Neck; 2015 May; 37(5):670-6. PubMed ID: 24596112
[TBL] [Abstract][Full Text] [Related]
19. Treatment Package Time in Node-Positive Cutaneous Head and Neck Squamous Cell Carcinoma.
Daniels CP; Bressel M; Corry J; Cole A; Chua MS; Tiong A; Hirshoren N; Dixon B; McDowell L
Pract Radiat Oncol; 2020; 10(1):29-35. PubMed ID: 31606546
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy with S-1 after curative chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck: Reanalysis of the ACTS-HNC study.
Kubota A; Nakatani E; Tsukahara K; Hasegawa Y; Takemura H; Terada T; Taguchi T; Nagahara K; Nakatani H; Yoshino K; Higaki Y; Iwae S; Beppu T; Hanamure Y; Tomita K; Kohno N; Kawabata K; Teramukai S; Fujii M;
PLoS One; 2018; 13(6):e0198391. PubMed ID: 29883463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
